Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome

Cronkhite-Canada Syndrome (CCS) is a rare non-hereditary gastroenterological polyposis syndrome without a clear etiology. Myelodysplastic syndromes (MDS) are clonal hematological disorders. Immune dysregulation has been posited as a contributor to the development of both. A 70-year-old man developed chronic diarrhea, dysgeusia, and onycholysis. Endoscopic evaluation and testing to exclude hereditary polyposis syndromes resulted in a diagnosis of CCS. Approximately 1 year later, he was noted to have persistent anemia, which was ultimately diagnosed as MDS. He was evaluated with a myeloid disorder next-generation sequencing panel and found to have mutations in <i>IDH2</i>, <i>SRSF2</i>, and <i>JAK2</i>. This is the second reported case characterizing concomitant MDS and CCS. This is the first case to report the development of MDS after the diagnosis and treatment of CCS. A successful management strategy for both disorders is outlined within this case report.

Authors

Institutions

Publication Details

Journal
Clinical Case Reports
Published
2025-07-30
DOI
https://doi.org/10.1002/ccr3.70602
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome

Cecilia Arana Yi, Jewel Samadder, Kevin G. Shim, Kevork Khadarian et al.
1 links
Clinical Case Reports
Acute Myeloid Leukemia Research
article

Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome

Cecilia Arana Yi, Jewel Samadder, Kevin G. Shim, Kevork Khadarian, Jiehao Zhou
article en

Abstract

Cronkhite-Canada Syndrome (CCS) is a rare non-hereditary gastroenterological polyposis syndrome without a clear etiology. Myelodysplastic syndromes (MDS) are clonal hematological disorders. Immune dysregulation has been posited as a contributor to the development of both. A 70-year-old man developed chronic diarrhea, dysgeusia, and onycholysis. Endoscopic evaluation and testing to exclude hereditary polyposis syndromes resulted in a diagnosis of CCS. Approximately 1 year later, he was noted to have persistent anemia, which was ultimately diagnosed as MDS. He was evaluated with a myeloid disorder next-generation sequencing panel and found to have mutations in <i>IDH2</i>, <i>SRSF2</i>, and <i>JAK2</i>. This is the second reported case characterizing concomitant MDS and CCS. This is the first case to report the development of MDS after the diagnosis and treatment of CCS. A successful management strategy for both disorders is outlined within this case report.

Clinical Case ReportsVol. 13(8)
WinnMed (US), Mayo Clinic in Arizona (US), Mayo Clinic Hospital (US), Mayo Clinic in Florida (US)
Good health and well-being
Openalex Percentile: Top 77%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.